塞尔美替尼增加了一线达卡巴嗪的疗效。

Selumetinib increases the efficacy of first-line dacarbazine.

出版信息

Cancer Discov. 2013 Jul;3(7):OF16. doi: 10.1158/2159-8290.CD-RW2013-129. Epub 2013 Jun 13.

DOI:10.1158/2159-8290.CD-RW2013-129

PMID:23847359

Abstract

Selumetinib plus dacarbazine prolongs progression-free survival in BRAF-mutant melanoma.

摘要

Selumetinib 联合达卡巴嗪可延长 BRAF 突变型黑色素瘤患者的无进展生存期。

相似文献

Selumetinib increases the efficacy of first-line dacarbazine.

Cancer Discov. 2013 Jul;3(7):OF16. doi: 10.1158/2159-8290.CD-RW2013-129. Epub 2013 Jun 13.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

Lancet Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun 2.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

Ann Oncol. 2014 May;25(5):968-74. doi: 10.1093/annonc/mdu054. Epub 2014 Feb 24.

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).

BMC Cancer. 2015 Jun 10;15:467. doi: 10.1186/s12885-015-1470-z.

Strides in melanoma announced: maximizing value comes next.

J Natl Cancer Inst. 2011 Jul 6;103(13):997-9. doi: 10.1093/jnci/djr254. Epub 2011 Jun 21.

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

Cancer. 2013 Feb 15;119(4):799-805. doi: 10.1002/cncr.27790. Epub 2012 Sep 12.

Is it good or bad to find a BRAF mutation?

J Clin Oncol. 2011 Apr 1;29(10):1229-30. doi: 10.1200/JCO.2010.34.0497. Epub 2011 Feb 22.

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).

Eur J Cancer. 2021 Jul;152:116-128. doi: 10.1016/j.ejca.2021.04.028. Epub 2021 Jun 4.

A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).

Anticancer Drugs. 2012 Aug;23(7):761-4. doi: 10.1097/CAD.0b013e328350737d.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

引用本文的文献

Understanding the biology of melanoma and therapeutic implications.

Hematol Oncol Clin North Am. 2014 Jun;28(3):437-53. doi: 10.1016/j.hoc.2014.02.007.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

塞尔美替尼增加了一线达卡巴嗪的疗效。

Selumetinib increases the efficacy of first-line dacarbazine.

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献